CN103923022B - A kind of 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds and synthetic method thereof and application - Google Patents

A kind of 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds and synthetic method thereof and application Download PDF

Info

Publication number
CN103923022B
CN103923022B CN201410169763.9A CN201410169763A CN103923022B CN 103923022 B CN103923022 B CN 103923022B CN 201410169763 A CN201410169763 A CN 201410169763A CN 103923022 B CN103923022 B CN 103923022B
Authority
CN
China
Prior art keywords
aryl
tetrahydro quinazoline
compounds
aminated compounds
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410169763.9A
Other languages
Chinese (zh)
Other versions
CN103923022A (en
Inventor
王石发
张志杰
鲍名凯
杨益琴
熊丝丝
徐徐
曹明珍
彭晗
吴君
谷文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Qingmu New Material Technology Co.,Ltd.
Original Assignee
Nanjing Forestry University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Forestry University filed Critical Nanjing Forestry University
Priority to CN201410169763.9A priority Critical patent/CN103923022B/en
Publication of CN103923022A publication Critical patent/CN103923022A/en
Application granted granted Critical
Publication of CN103923022B publication Critical patent/CN103923022B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a kind of 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds and synthetic method thereof and application.The synthetic method of this compounds is: be 1) raw material with α-pinene, obtain isopinocampheol through hydroboration-oxidation; 2) under condition of ice bath, PCC oxydehydrogenation obtains isopinocamphone; 3) under basic catalyst effect, isopinocamphone and aromatic aldehyde condensation obtain 4-aryl methylene-3-pinone compounds; 4) last under sodium hydroxide or potassium tert.-butoxide catalysis, 4-aryl methylene-3-pinone and Guanidinium hydrochloride react and obtain 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds.This compounds shows good bacteriostatic activity to bacterium and fungi, and has good anti-tumor activity to human breast cancer cell line Bcap-37 and human lung cancer cell A549.

Description

A kind of 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds and synthetic method thereof and application
Technical field
The invention belongs to organic compound technical field, be specifically related to a kind of 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds and synthetic method thereof and application.
Background method
Quinazoline, i.e. benzo pyrimidine, be made up of a phenyl ring and a pyrimidine ring condensed ring.Research finds, the compound containing quinazoline skeleton has multiple pharmacology and biological activity, as: anti-inflammatory, antibacterial, tuberculosis, anti-diabetic, AntiHIV1 RT activity and the effect such as antitumor.
Since Fry in 1994 etc. find that 4-anilinoquinazoline PD153035 (1) is as the kinase whose specific inhibitor of EGFR TYR, quinazoline compounds becomes one of focus of cancer therapy drug development, and has developed the first-generation and s-generation target agent.First-generation EGFR reversible inhibitor Gefitinib ZD1839 (Iressa, 2) and erlotinib OSI-774 (Tarceva, 3) etc. are because of its good antitumour activity commercialization.
Ouyang etc. have synthesized a series of 3-aryl-quinazoline-4-one derivatives (4).Bioassay result shows that this series compound all has certain inhibit activities to gibberella saubinetii (Gibberellazeae), capsicum withered (Fusariumoxysporum), apple decay (Valsamali) three kinds of germs.Lubiniwardo etc. have applied for replacing the patent of two (the dialkyl amido)-quinazoline (5) of 2,4-as antiseptic-germicide, and this compounds is all better to staphylococcus, actinomycetes and colibacillary inhibition.Quinazoline-4-one is coupled together by secondary amine NH and another quinazoline molecules and has prepared compound (6) by Tiwari etc., and it reaches 83.3% to the inhibiting rate of Aspergillus flavus under 10 μ g/mL concentration.
Summary of the invention
Goal of the invention: for the deficiencies in the prior art, the object of the present invention is to provide a kind of 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds, good restraining effect can be shown to bacterium and fungi, to human breast cancer cell line Bcap-37 and human lung cancer cell A549, there is certain anti-tumor activity; Another object of the present invention is to the synthetic method that above-claimed cpd is provided.The present invention also has an object to be to provide the application of above-claimed cpd.
Technical scheme: in order to realize foregoing invention object, the technical solution adopted in the present invention is:
4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds, its structural formula is:
In formula, Ar is selected from fluorophenyl, rubigan, Chloro-O-Phenyl, p-nitrophenyl, phenyl, p-methylphenyl, p-methoxyphenyl and furyl.
This 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds is new compound, comprises compound (4a) ~ compound (4h), concrete title and structural formula as follows:
Compound (4a): 6,6,8-trimethylammonium-5,7-methylene bridge-4-(4 '-fluorophenyl)-5,6,7,8-tetrahydro quinazoline-2-amine;
Compound (4b): 6,6,8-trimethylammonium-5,7-methylene bridge-4-(4 '-chloro-phenyl-)-5,6,7,8-tetrahydro quinazoline-2-amine;
Compound (4c): 6,6,8-trimethylammonium-5,7-methylene bridge-4-(2 '-chloro-phenyl-)-5,6,7,8-tetrahydro quinazoline-2-amine;
Compound (4d): 6,6,8-trimethylammonium-5,7-methylene bridge-4-(4 '-nitrophenyl)-5,6,7,8-tetrahydro quinazoline-2-amine;
Compound (4e): 6,6,8-trimethylammonium-5,7-methylene bridge-4-phenyl-5,6,7,8-tetrahydro quinazoline-2-amine;
Compound (4f): 6,6,8-trimethylammonium-5,7-methylene bridge-4-(4 '-aminomethyl phenyl)-5,6,7,8-tetrahydro quinazoline-2-amine;
Compound (4g): 6,6,8-trimethylammonium-5,7-methylene bridge-4-(4 '-p-methoxy-phenyl)-5,6,7,8-tetrahydro quinazoline-2-amine;
Compound (4h): 6,6,8-trimethylammonium-5,7-methylene bridge-4-furyl-5,6,7,8-tetrahydro quinazoline-2-amine;
A kind of synthetic method of 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds, processing step is as follows:
(1) be raw material with α-pinene, obtain isopinocampheol through hydroboration-oxidation;
(2) isopinocampheol dehydrogenation under oxygenant effect obtains isopinocamphone;
(3) under catalyst action, isopinocamphone and aromatic aldehyde condensation obtain serial 4-aryl methylene-3-pinone compounds;
(4) under sodium hydroxide solution or potassium tert.-butoxide catalysis, 4-aryl methylene-3-pinone compounds and Guanidinium hydrochloride cyclisation obtain 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds.
Processing step (1) reaction formula:
Processing step (2) reaction formula:
Processing step (3) reaction formula:
Processing step (4) reaction formula:
Described 4-aryl-5,6,7,8-tetrahydrochysene frustrates the application of beautiful jade-2-aminated compounds in antibacterial.
Described bacterium is intestinal bacteria, streptococcus aureus, subtilis, Pseudomonas fluorescens, Candida albicans, aspergillus niger, candida tropicalis.
The described application of 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds in inhibition tumor cell.
Described tumour cell is human breast cancer cell line Bcap-37 and human lung cancer cell A549.
To synthesized 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds, adopt doubling dilution test compounds to the minimum inhibitory concentration of bacterium and fungi; Adopt cell scratch method test compounds to the anti-migratory activity of human breast cancer cell line Bcap-37; Adopt mtt assay test compounds to the inhibit activities of human lung cancer cell A549.
Beneficial effect: compared with prior art, advantage of the present invention is as follows:
1) the main component α-pinene in natural extract turps the abundantest is adopted, utilize its specific space structure synthesizing new 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds, screening has the compound of Efficient antibacterial activity and anti-tumor activity.Expand the source of fungistat and antitumor drug.
2) this 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds is to intestinal bacteria (E.coli), streptococcus aureus (S.aureus), subtilis (B.subtilis), Pseudomonas fluorescens (P.fluorescens), and Candida albicans (C.albicans), aspergillus niger (A.niger), candida tropicalis (G.tropicalis) etc. have good inhibit activities.
3) this 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds has good anti-tumor activity to human breast cancer cell line Bcap-37 and human lung cancer cell A549.
4) for designing the analysis of novel azaheterocyclic compound and structure activity relationship, certain reference value is provided, significant to the terebinthine field that utilizes of expansion China.
Embodiment
Below in conjunction with specific embodiment, the present invention is further described.
The preparation of embodiment 1 isopinocampheol
In the present embodiment, the preparation of isopinocampheol, disclosed in reference literature [synthesis of left-handed isopinocamphone, organic chemistry, 2007,27 (12): 1612 ~ 1617], method is carried out.Prepared isopinocampheol is white needles, productive rate 81%, purity 99.0% (GC).
The preparation of embodiment 2 isopinocamphone
In the present embodiment, the preparation of isopinocamphone, disclosed in reference literature [synthesis of left-handed isopinocamphone, organic chemistry, 2007,27 (12): 1612 ~ 1617], method is carried out.Also can shine following method: add in there-necked flask by 50.0g isopinocampheol and 500mL methylene dichloride, at 0 ~ 5 DEG C, add 84.5gPCC in batches, stir 10h at 0 ~ 5 DEG C.Add 300mL anhydrous diethyl ether dilute reaction solution, with diatomite filtration, with washed with diethylether filter cake twice, merge hydrochloric acid and saturated common salt water washing that organic phase uses 5% respectively, then use anhydrous Na 2sO 4dry.Removing desolventizing with gyroscope, the resistates of gained is carried out underpressure distillation, and the cut between collecting 105 ~ 115 DEG C, obtains anhydrous oily liquids, purity 98.0% (GC), yield 74%.
The preparation of embodiment 34-aryl methylene-3-pinone 3a ~ 3h
Reaction formula:
Logical method: add the different pine of 0.O1mol successively and send ketone and 0.O1mol aromatic aldehyde in 5OmL there-necked flask, add the ethanolic soln of 10% sodium ethylate that 15mL prepares, react 6h under induction stirring under 40 DEG C of conditions, GC monitoring display reaction completes.After cooling, reaction solution is extracted with ethyl acetate, through saturated common salt water washing to neutral, and anhydrous Na SO 4obtain crude product after dry, concentrated, obtain 4-aryl methylene-3-pinone compound 3 through ethyl alcohol recrystallization a~ 3h.
The preparation of embodiment 44-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds 4a ~ 4h
Reaction formula:
Logical method: in the 5OmL there-necked flask being furnished with thermometer and condenser, add 0.O2mo14-aryl methylene-3-pinone 3 successively, 0.06 ~ 0.08mol Guanidinium hydrochloride, dehydrated alcohol 15mL, add 0.10mol potassium tert.-butoxide under induction stirring, oil bath pan is heated to back flow reaction 12 ~ 18h (GC tracking monitor).After cooling, ethyl acetate (50mL × 3) extracts, saturated common salt is washed, through anhydrous sodium sulfate drying, filtration, concentrated after obtain oily liquids, adopt thin layer silica gel chromatographic column [sherwood oil: ethyl acetate=8:1 (V/V)] purifying, obtain 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds 4a ~ 4h, purity is all more than 99%.
The precursor skeleton carbon atoms numbered of 4-aryl-5,6,7, the 8-tetrahydro quinazoline-2-aminated compounds of synthesis is shown below:
Compound (4a) product characterizes: white solid, yield 57.5%; M.p.190 ~ 192 DEG C; IR (KBr) ν: 3293,3170,2975,1626 (C=N), 1558,1549 (N-H), 1447,1154 (C-N), 846cm -1; 1hNMR (300MHz, DMSO-d 6) δ: 0.70 (s, 3H), 1.15 (d, J=7.6Hz, 1H), 1.28 (d, J=7.1Hz, 3H), 1.39 (s, 3H), 2.00 ~ 2.04 (m, 1H), 2.39 ~ 2.46 (m, 1H), 2.85 (t, J=7.8Hz, 1H), 2.95 ~ 3.01 (m, 1H), 4.91 (s, 2H, N-H), 7.03 (t, 2H), 7.31 (dd, J=7.6Hz, 2H); 13cNMR (300MHz, DMSO-d 6) δ: 17.72,21.03,26.27,29.08,39.09,41.10,42.03,46.32,115.34,115.30,126.20,130.74,134.09,161.25,164.63,172.18; MS (70eV) m/z (%): 297 (M +, 24), 282 (M +-CH 3, 52).
Compound (4b) product characterizes: white solid, yield 57.3%; M.p.185 ~ 187 DEG C; IR (KBr) ν: 3311,3171,2968,1622 (C=N), 1596,1549 (N-H), 1490,1206 (C-N), 836cm -1; 1hNMR (300MHz, DMSO-d 6) δ: 0.71 (s, 3H), 1.18 (d, J=9.6Hz, 1H), 1.28 (d, J=9.1Hz, 3H), 1.33 (s, 3H), 2.03 ~ 2.05 (m, 1H), 2.44 ~ 2.47 (m, 1H), 2.80 (t, J=5.8Hz, 1H), 2.93 ~ 2.95 (m, 1H), 6.35 (s, 2H, N-H), 7.36 (d, J=8.4Hz, 2H), 7.50 (d, J=8.6Hz, 3H); 13cNMR (300MHz, DMSO-d 6) δ: 17.44,20.78,25.91,28.74,38.42,40.57,41.47,45.66,123.59,128.04,130.49,133.18,136.68,159.74,161.78,170.94; MS (70eV) m/z (%): 313 (M +, 19), 298 (M +-CH 3, 41).
Compound (4c) product characterizes: white solid, yield 50.7%; M.p.173 ~ 175 DEG C; IR (KBr) ν: 3481,3352,2946,1616 (C=N), 1573,1546 (N-H), 1478,1183 (C-N), 756cm -1; 1hNMR (300MHz, DMSO-d 6) δ: 0.72 (s, 3H), 1.26 (d, J=9.3Hz, 3H), 1.50 (s, 3H), 1.70 (d, J=9.85Hz, 1H), 2.04 (d, J=6.1Hz, 1H), 2.21 (s, 1H), 2.43 ~ 2.46 (m, 1H), 6.42 (s, 2H, N-H), 7.21 (d, J=9.45Hz, 1H), 7.40 ~ 7.44 (dd, J=3.9Hz, 7.3Hz, 2H), 7.50 (d, J=9.8Hz, 1H); 13cNMR (300MHz, DMSO-d 6) δ: 23.70,26.10,27.13,30.97,40.88,43.66,52.80,73.20,123.79,127.11,129.09,129.83,130.80,131.41,137.02,160.19,162.32,169.40; MS (70eV) m/z (%): 313 (M +, 10), 298 (M +-CH 3, 30).
Compound (4d) product characterizes: yellow solid, yield 54.6%; M.p.240 ~ 242 DEG C; IR (KBr) ν: 3316,3189,2977,1636 (C=N), 1573,1551 (N-H), 1519,1209 (C-N), 817cm -1; 1hNMR (300MHz, DMSO-d 6) δ: 0.72 (s, 3H), 1.19 (d, J=9.8Hz, 1H), 1.35 (d, J=9.4Hz, 3H), 1.52 (s, 3H), 1.74 (d, J=9.7Hz, 1H), 2.08 (t, J=6.1Hz, 1H), 2.50 (t, J=5.8Hz, 1H), 2.72 ~ 2.75 (m, 1H), 6.53 (s, 2H, N-H), 7.62 (d, J=8.75Hz, 2H), 8.31 (d, J=8.75Hz, 2H); 13cNMR (300MHz, DMSO-d 6) δ: 23.76,26.29,26.98,30.96,41.64.43.82,52.84,73.33,123.01,123.43,130.15,144.41,147.36,159.66,162.39,170.82; MS (70eV) m/z (%): 324 (M +, 18), 309 (M +-CH 3, 46).
Compound (4e) product characterizes: white solid, yield 51.8%; M.p.170 ~ 172 DEG C; IR (KBr) ν: 3323,3205,2968,1623 (C=N), 1565,1565 (N-H), 1490,1207 (C-N), 765,702cm -1; 1hNMR (300MHz, DMSO-d 6) δ: 0.72 (s, 3H), 1.16 (d, J=9.7Hz, 1H), 1.27 (d, 3H), 1.38 (s, 3H), 1.98 ~ 2.05 (m, 1H), 2.38 ~ 2.50 (m, 1H), 2.84 (t, J=5.95Hz, 1H), 2.93 ~ 2.95 (m, 1H), 6.35 (s, 2H, N-H), 7.36 (d, J=5.85Hz, 5H); 13cNMR (300MHz, DMSO-d 6) δ: 17.54,20.67,20.97,25.95,28.87,40.57,41.60,45.80,123.77,132.69,137.96,138.07,161.21,161.89,170.78,172.05; MS (70eV) m/z (%): 279 (M +, 29), 264 (M +-CH 3, 56).
Compound (4f) product characterizes: white solid, yield 48.9%; M.p.189 ~ 191 DEG C; IR (KBr) ν: 3305,3178,2971,1623 (C=N), 1572,1560 (N-H), 1513,1203 (C-N), 811cm -1; 1hNMR (300MHz, DMSO-d 6) δ: 0.76 (s, 3H), 1.26 (d, J=9.8Hz, 1H), 1.35 (d, J=9.3Hz, 3H), 1.36 (s, 3H), 2.07 ~ 2.08 (m, 1H), 2.39 (s, 3H, Ar-CH 3), 2.47 ~ 2.48 (m, 1H), 2.94 (t, J=5.8Hz, 1H), 3.05 ~ 3.07 (m, 1H), 5.79 (s, 2H, N-H), 7.25 (s, 4H); 13cNMR (300MHz, DMSO-d 6) δ: 17.83,21.12,26.20,29.01,38.75,41.10,41.99,46.42,125.89,128.84,134.21,138.85,161.02,162.23,171.94,175.74; MS (70eV) m/z (%): 293 (M +, 45), 278 (M +-CH 3, 83).
Compound (4g) product characterizes: white solid, yield 46.4%; M.p.203 ~ 205 DEG C; IR (KBr) ν: 3302,3176,2991,1608 (C=N), 1580,1553 (N-H), 1514,1251 (C-O-C), 820cm -1; 1hNMR (300MHz, DMSO-d 6) δ: 0.71 (s, 3H), 1.35 (d, J=9.4Hz, 3H), 1.51 (s, 3H), 1.72 (d, J=9.7Hz, 1H), 2.06 (t, J=5.95Hz, 1H), 2.42 ~ 2.43 (m, 1H), 2.85 (t, J=5.9Hz, 1H), 3.79 (s, 3H, Ar-OCH 3), 5.79 (s, 2H, N-H), 7.00 (d, J=8.7Hz, 2H), 7.31 (d, J=8.7Hz, 2H); 13cNMR (300MHz, DMSO-d 6) δ: 23.71,26.23,27.03,30.98,40.00,41.68,43.61,52.83,55.10,113.36,122.45,130.10,130.32,159.41,161.40,162.14,169.78; MS (70eV) m/z (%): 309 (M +, 52), 294 (M +-CH 3, 70).
Compound (4h) product characterizes: yellow solid, yield 45.2%; M.p.184 ~ 186 DEG C; IR (KBr) ν: 3319,3192,2927,1625 (C=N), 1554,1540 (N-H), 1455,1203 (C-N), 743cm- 1; 1hNMR (300MHz, DMSO-d 6) δ: 0.63 (s, 3H), 1.17 (d, J=9.2Hz, 1H), 1.25 (d, J=9.2Hz, 3H), 1.36 (s, 3H), 1.99 ~ 2.01 (m, 1H), 2.47 ~ 2.50 (m, 1H), 2.89 ~ 2.91 (m, 1H), 3.50 (t, J=6.8Hz, 1H), 6.31 (s, 2H, N-H), 6.58 (m, 1H), 6.92 (d, J=5.65Hz, 1H), 7.79 (t, J=2.8Hz, 1H); 13cNMR (300MHz, DMSO-d 6) δ: 14.05,17.61,20.69,21.01,26.20,28.46,41.02,45.53,111.61,112.26,122.34,144.19,149.55,152.75,161.72,171.80; MS (70eV) m/z (%): 269 (M +, 26), 254 (M +-CH 3, 46).
The physical properties of 8 prepared novel 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compoundss, as shown in table 1.
The physical properties of table 1 compound (1) ~ (8)
Compound Molecular formula Molecular weight Outward appearance Fusing point/DEG C
4a C 18H 20N 3F 297.4 White solid 190～192
4b C 18H 20N 3Cl 313.8 White solid 185～187
4c C 18H 20N 3Cl 313.8 White solid 173～175
4d C 18H 20N 4O 2 326.2 Yellow solid 240～242
4e C 18H 21N 3 279.4 White solid 170～172
4f C 19H 23N 3 293.4 White solid 189～191
4g C 19H 23N 3O 309.4 White solid 203～205
4h C 16H 19N 3O 269.3 Yellow solid 184～186
The biological activity test of embodiment 54-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds
1) bacteriostatic activity test
Minimum inhibitory concentration (MinimumInhibitoryConcentration, MIC) adopts doubling dilution to measure.Concrete operations: first the 2nd hole is added 75 μ L sterilized waters to the 12nd hole, again testing compound and positive reference substance KETOKONAZOL and amikacin are added the 1st hole with the solution 150 μ L that DMSO is made into 500 μ g/mL respectively, compound and positive control solution are carried out doubling dilution respectively in 96 hole analysis plates, a series of concentration gradient (500 μ g/mL ~ 0.244 μ g/mL) is made into from the 1 to the 12 hole, every hole is containing 75 μ L solution, using pure DMSO as reference, then in each hole, add the bacteria suspension that 75 μ L prepare in advance, fully mix.Finally 96 hole analysis plates are placed in 30 DEG C of incubators, microbial culture 24h, observes after fungus culture 48h, and the concentration corresponding using the hole not producing muddy minimum concentration is as the minimum inhibitory concentration of this sample to this test bacterium.Each sample tests bacterium in triplicate to often kind, results averaged.The minimum inhibitory concentration of compound (4a) ~ (4h) the results are shown in Table shown in 2.
The minimum inhibitory concentration (MIC) of table 2 compound (4a) ~ (4h)
apositive control (positivecontrol): bacterium is kantlex, fungi is KETOKONAZOL.
From table 2 data, 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds has good inhibit activities to intestinal bacteria (E.coli), streptococcus aureus (S.aureus), subtilis (B.subtilis), Pseudomonas fluorescens (P.fluorescens), Candida albicans (C.albicans), aspergillus niger (A.niger), candida tropicalis (G.tropicalis) etc.Wherein compound (4b) inhibition concentration to streptococcus aureus reaches 3.9 μ g/mL.
2) anti-tumor activity test
Adopt cell scratch experiment assessing compound (4a) ~ (4h) to the inhibit activities of human breast cancer cell line Bcap-37.Wherein MCF-7 cell is provided by Institute Of Chinese Materia Medica Of China Academy of Chinese Medical Sciences.Concrete grammar is as follows: draw horizontal line every about 0.5 ~ 1cm behind at 6 orifice plates, ensures every hole at least through 5 lines; About 5 × 10 are added in hole 5individual MCF-7 cell; Horizontal in " one " stroke on monolayer cell with rifle head after spending the night, PBS washes cell 3 times, removes the cell under drawing, and adds the testing compound 4 that serum free medium and concentration are 20.0 μm of ol/L, 40.0 μm of ol/L and 80.0 μm ol/L respectively; Put into 37 DEG C, 5%CO 2sample after cultivating 24h in incubator, take pictures.Test result is shown in Table 3.
Table 3 compound (4a) ~ (4h) is to the inhibit activities of MCF-7 cell
Compound MCF-7(μmol/L)
4a 20.0
4b 20.0
4c 80.0
4d >100
4e 20.0
4f >100
4g >100 9 -->
4h 40.0
As can be seen from Table 3, the 4-aryl-5 of synthesis, 6,7, in 8-tetrahydro quinazoline-2-aminated compounds, part of compounds has good inhibit activities to tumour cell MCF-7, and wherein compound (4a), (4b), (4e) inhibition concentration are 20 μm of ol/L.
Adopt MTT experiment assessing compound (4a), (4b) and (4e) to the increment inhibit activities of human lung cancer cell A549, wherein, A549 cell is provided by Institute Of Chinese Materia Medica Of China Academy of Chinese Medical Sciences.Concrete grammar is as follows: after cell 0.25% pancreatin of logarithmic phase/EDTA digestion, be configured to certain density single cell suspension, and the difference according to vitro growth rates is inoculated in 96 flat boards by 800-2000/hole, and every hole adds cell suspension 100 μ L.The fresh culture containing the testing compound of different concns and coordinative solvent contrast is added after 24h, every hole adds 100 μ L (DMSO final concentration < 0.1%), continue to cultivate 48h at 37 DEG C after, abandon supernatant, every hole adds the serum free medium containing 0.5mg/mLMTT of the fresh configuration of 100 μ L, continue to cultivate 4h, after abandoning supernatant, every hole adds 150 μ LDMSO dissolving MTT first hairpin precipitations, after microoscillator vibration mixing, microplate reader is at reference wavelength 450nm, optical density value (OD) is measured under determined wavelength 570nm condition, with the tumour cell of solvent control process for control group, with the inhibiting rate of following formulae discovery drug on tumor cell, and calculate IC by middle effect agenda 50.Test result is shown in Table 4.Wherein, inhibiting rate=(control group mean OD value-administration group mean OD value)/control group mean OD value × 100%.
Table 4 compound (4a), (4b), (4e) are to the inhibit activities of A549 cell
Compound A549(IC 50，μM)
(4a) 6.74
(4b) 18.21
(4e) 18.02
As can be seen from Table 4, compound (4a), (4b), (4e) all have good inhibit activities to tumour cell A549, and wherein the inhibit activities of compound (4a) is the strongest, IC 50=6.74 μMs.

Claims (6)

1.4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds, is characterized in that: structural formula is:
In formula, Ar is selected from fluorophenyl, rubigan, Chloro-O-Phenyl, p-nitrophenyl, phenyl, p-methylphenyl, p-methoxyphenyl and furyl.
2. the synthetic method of 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds according to claim 1, it is characterized in that, processing step is as follows:
(1) be raw material with α-pinene, obtain isopinocampheol through hydroboration-oxidation;
(2) isopinocampheol dehydrogenation under oxygenant effect obtains isopinocamphone;
(3) under catalyst action, isopinocamphone and aromatic aldehyde condensation obtain serial 4-aryl methylene-3-pinone compounds;
(4) under sodium hydroxide solution or potassium tert.-butoxide catalysis, 4-aryl methylene-3-pinone compounds and Guanidinium hydrochloride cyclisation obtain 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds.
3. 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds according to claim 1 is preparing the application in antibacterial medicines.
4. application according to claim 3, is characterized in that: described bacterium is intestinal bacteria, streptococcus aureus, subtilis, Pseudomonas fluorescens, Candida albicans, aspergillus niger, candida tropicalis.
5. 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds according to claim 1 is for the preparation of the application in the medicine of inhibition tumor cell.
6. application according to claim 5, is characterized in that: described tumour cell is human breast cancer cell line Bcap-37 and human lung cancer cell A549.
CN201410169763.9A 2014-04-24 2014-04-24 A kind of 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds and synthetic method thereof and application Active CN103923022B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410169763.9A CN103923022B (en) 2014-04-24 2014-04-24 A kind of 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds and synthetic method thereof and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410169763.9A CN103923022B (en) 2014-04-24 2014-04-24 A kind of 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds and synthetic method thereof and application

Publications (2)

Publication Number Publication Date
CN103923022A CN103923022A (en) 2014-07-16
CN103923022B true CN103923022B (en) 2016-03-23

Family

ID=51141444

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410169763.9A Active CN103923022B (en) 2014-04-24 2014-04-24 A kind of 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds and synthetic method thereof and application

Country Status (1)

Country Link
CN (1) CN103923022B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105541795B (en) * 2016-02-22 2018-01-19 南京林业大学 Pyridyl-pyrimidine class compound and its synthetic method and application
CN110551070A (en) * 2018-05-30 2019-12-10 南京林业大学 Synthesis of camphoryl pyrimidine compounds and antitumor activity thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333122A (en) * 2013-06-25 2013-10-02 南京林业大学 Pinanyl-2-aminopyrimidine compounds as well as synthesis and application thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333122A (en) * 2013-06-25 2013-10-02 南京林业大学 Pinanyl-2-aminopyrimidine compounds as well as synthesis and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
左旋异松蒎酮的合成;王石发，等;《有机化学》;20071231;第27卷(第12期);第1612-1617页 *

Also Published As

Publication number Publication date
CN103923022A (en) 2014-07-16

Similar Documents

Publication Publication Date Title
Rai et al. Novel chromeno [2, 3-b]-pyrimidine derivatives as potential anti-microbial agents
CN103275018B (en) 4-[the chloro-4-substituted anilinic of 3-]-6-substituted formyl amino-quinazoline compound and Synthesis and applications
Gupta Efficient synthesis of antifungal active 9-substituted-3-aryl-5H, 13aH-quinolino [3, 2-f][1, 2, 4] triazolo [4, 3-b][1, 2, 4] triazepines in ionic liquids
CN101628912A (en) Anti-tumor compound containing triazole heterocyclic structure and application thereof
CN103951566B (en) N-alkyl-1,2,3,4,5,6-hexahydro-1,1,5,5-tetramethyl-7H-2,4 alpha-methanonaphthalene-7-amine compound as well as synthetic method and application thereof
CN103965118B (en) One class pinane base-2-amino-metadiazine compound and synthetic method thereof and application
CN103333122A (en) Pinanyl-2-aminopyrimidine compounds as well as synthesis and application thereof
CN103923022B (en) A kind of 4-aryl-5,6,7,8-tetrahydro quinazoline-2-aminated compounds and synthetic method thereof and application
CN107311905B (en) A kind of nopinone thiosemicarbazone derivative and its preparation method and application
CN103420990B (en) 7-oxygen, sulphur or azepine substituted cumarin and derivative thereof and purposes
CN106220631B (en) A kind of 7 fluorine replace Isaindigotone derivative and preparation method thereof and are preparing the application in anticancer drug
CN107417580A (en) One kind has the gossypol L arginine Schiff bases compounds and its synthetic method of antitumor activity
CN104230889A (en) Ciprofloxacin derivatives and preparation method and use of ciprofloxacin derivatives
CN102241657A (en) Synthesis of isoflavone compound through Stille crossed coupling reaction
CN104016957A (en) 7-methyl-3-geranyl flavone and 7-methyl-3-isopentene group flavone as well as preparation method and application thereof
CN110372588A (en) A kind of 4- amido quinoline compound and its preparation method and application
CN103435560B (en) Synthesis and application of aceanthrylene [1,2-b] quinoxaline derivative with flexible side chain
CN103980217B (en) One class pinane isoxazole compounds and synthetic method thereof and application
CN107540680A (en) A kind of lappaconitine acetal analog derivative and its synthetic method with antitumor activity
CN102911177A (en) 7-(4-chlorphenyl)-5,6-dihydro-7aH-benzo[h]1,2,4-triazolo[3,4-b]quinazoline-5,6-diketone and synthetic method thereof
CN106397433B (en) Three pyridinium hydroxide of 2- (2- pyridine) -6- (the chloro- 3- trifluoromethylbenzoyl of 2-) -5,7,8- simultaneously [4,3-d] pyrimidine and preparation method thereof
CN109111396A (en) A kind of quinoline aromatic ethylene analog derivative and its preparation method and application
Salem et al. Synthesis, reactivity and antimicrobial activity of coumarinic and chromonic heterocycles
CN115611818B (en) Pyrimidine amine compound containing bicyclo-monoterpene structure, and preparation method and application thereof
CN104003970B (en) Natural product Albanin A/E analogue and its preparation method and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20181228

Address after: 225002 Chen Ci Village, Shatou Town, Guangling District, Yangzhou City, Jiangsu Province

Patentee after: YANGZHOU YIYANG TECHNOLOGY DEVELOPMENT Co.,Ltd.

Address before: No. 159, dragon pan Road, Nanjing, Jiangsu

Patentee before: Nanjing Forestry University

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220826

Address after: 225000 Lidian town science and Technology Pioneer Park, Guangling District, Yangzhou City, Jiangsu Province

Patentee after: Yangzhou Shengning Information Technology Co.,Ltd.

Address before: 225002 Chen Ci Village, Shatou Town, Guangling District, Yangzhou City, Jiangsu Province

Patentee before: YANGZHOU YIYANG TECHNOLOGY DEVELOPMENT Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230306

Address after: Room 1118, Building D, No. 606, Ningliu Road, Jiangbei New District, Nanjing, Jiangsu, 210000

Patentee after: Nanjing Qingmu New Material Technology Co.,Ltd.

Address before: 225000 Lidian town science and Technology Pioneer Park, Guangling District, Yangzhou City, Jiangsu Province

Patentee before: Yangzhou Shengning Information Technology Co.,Ltd.

TR01 Transfer of patent right